Chimeric Therapeutics Ltd
ASX:CHM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Chimeric Therapeutics Ltd
Selling, General & Administrative
Chimeric Therapeutics Ltd
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Chimeric Therapeutics Ltd
ASX:CHM
|
Selling, General & Administrative
-AU$7.4m
|
CAGR 3-Years
12%
|
CAGR 5-Years
-158%
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Selling, General & Administrative
-$50.7m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-7%
|
|
|
CSL Ltd
ASX:CSL
|
Selling, General & Administrative
-$2.7B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-12%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Selling, General & Administrative
-AU$3m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Selling, General & Administrative
-AU$192.6m
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Selling, General & Administrative
-AU$5.3m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-11%
|
|
Chimeric Therapeutics Ltd
Glance View
Chimeric Therapeutics Ltd. develops Chlorotixin CAR-T technology based cell therapies for the curation of solid tumors. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-01-18. The firm's technology known as CLTX-CAR T, uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. The CAR T cell is an immune T cell taken from a patient’s blood which is sent to a lab where it is re-programmed to become a charged guided missile, to seek out a specific target on the surface of a cancer cell.
See Also
What is Chimeric Therapeutics Ltd's Selling, General & Administrative?
Selling, General & Administrative
-7.4m
AUD
Based on the financial report for Jun 30, 2025, Chimeric Therapeutics Ltd's Selling, General & Administrative amounts to -7.4m AUD.
What is Chimeric Therapeutics Ltd's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-158%
Over the last year, the Selling, General & Administrative growth was 22%. The average annual Selling, General & Administrative growth rates for Chimeric Therapeutics Ltd have been 12% over the past three years , -158% over the past five years .
